Bone News and Research

RSS

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.

16 Sep 2010

bluebird bio publishes LentiGlobin gene therapy clinical trial data results

bluebird bio an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced publication in the journal Nature of its promising Phase 1/2 data highlighting positive results of LentiGlobin gene therapy treatment in a young adult with severe beta-thalassemia, a blood disorder that is one of the most frequent inherited diseases.

16 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Center report in the Sept. 16 New England Journal of Medicine.

16 Sep 2010

Gene network behind hardening of arteries, coronary heart disease identified

A gene network behind hardening of the arteries and coronary heart disease has been identified by a team of scientists from Australia, Europe and the United Kingdom. Their findings expose potential targets for the treatment of heart disease.

16 Sep 2010

Amedica Corporation receives patents for total disc replacement technology

Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted two United States patents for its total disc replacement (TDR) technology that features the use of silicon nitride in the construction of the complete implant.

16 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

Acceleron Pharma named as one of "Fierce 15" for 2010

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced that it has been selected by the editors of FierceBiotech as one of the "Fierce 15" for 2010, an annual list of the top 15 most promising companies in the biotech industry.

15 Sep 2010

Population-specific identification criteria helps determine human remains in Chile earthquake

New research from North Carolina State University will help medical examiners and others identify human remains of those killed during the recent earthquake in Chile, as well as the bodies of the "disappeared" who were killed during the Pinochet administration.

15 Sep 2010

BioCryst reports results from forodesine studies for CTCL and CLL

BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).

15 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

OrthoAccel Technologies announces commercial plans for United Kingdom

OrthoAccel Technologies, Inc. has announced commercial plans for the United Kingdom that entail considerable business activity and economic impact. Last year, the Company hired a Director of Sales based in Wales. Recently, a full-market UK release of the AcceleDent System was reported. In conjunction with this product introduction at the British Orthodontic Conference, OrthoAccel has publicized plans to host a private lecture and reception to provide scientific data and education to doctors on this new technology that shortens orthodontic treatment time.

15 Sep 2010

SLActive chemical surfaces promote dental bone integration

Dental implants have offered a successful way to restore teeth for more than 20 years. New challenges for improving the process include shortening the time to restore functionality and meeting aesthetic demands. Altering implant surfaces to help promote bone integration is one solution. SLActive, a new chemically modified surface for titanium, the standard material of which implants are constructed, has shown positive results in this area.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results published in the September issue of the American Heart Journal.

15 Sep 2010

Wintherix announces WX04554 molecule can cause bone healing

Wintherix, LLC, a privately held biotechnology company focusing on bone healing and regenerative medicine, today announced that WX04554, a potent small molecule activator of the Wnt pathway, has been designated as a lead drug for clinical development in bone healing and repair indications.

15 Sep 2010

ThermoGenesis 2010 fourth quarter revenue increases to $7.2 million

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today that revenues for the fourth quarter of fiscal 2010 were $7.2 million versus revenues of $4.0 million for the same quarter a year ago. Revenues in the third quarter of fiscal 2010 were $4.8 million.

15 Sep 2010

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

Stemedica Cell Technologies, Inc., a world leader in adult stem cell manufacturing and research, announced today that it has completed its proprietary master bank of mesenchymal bone marrow-derived stem cells.

14 Sep 2010

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Over a 1000 experts from the world will participate in the Osteoarthritis Research Society International (OARSI) congress, under the Presidency of the Belgian Professor Yves Henrotin (University of Liège).

14 Sep 2010

ThermoGenesis retains compliance with NASDAQ listing standards

ThermoGenesis Corp. a leading supplier of innovative products and services that process and store adult stem cells, said today that it has been informed by NASDAQ that the Company is in compliance with all NASDAQ listing standards, including the minimum price bid requirement.

14 Sep 2010

Bone News and Research

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

bluebird bio publishes LentiGlobin gene therapy clinical trial data results

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

Gene network behind hardening of arteries, coronary heart disease identified

Amedica Corporation receives patents for total disc replacement technology

Johns Hopkins offers sources who can answer queries on prostrate cancer

Acceleron Pharma named as one of "Fierce 15" for 2010

Population-specific identification criteria helps determine human remains in Chile earthquake

BioCryst reports results from forodesine studies for CTCL and CLL

Phase II clinical trial shows GTx-758 reduces serum free testosterone

OrthoAccel Technologies announces commercial plans for United Kingdom

SLActive chemical surfaces promote dental bone integration

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

Wintherix announces WX04554 molecule can cause bone healing

ThermoGenesis 2010 fourth quarter revenue increases to $7.2 million

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

ThermoGenesis retains compliance with NASDAQ listing standards

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News